ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes [Yahoo! Finance]
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes